Molecular Partner…
CHCHFMolecular Partners AG (SW:MOLN) — Biotechnology: Biological Products (No Diagnostic Substances). Numero di borse in cui sono quotate le azioni della società: 3. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- molecularpartners.com
- Settore
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede Centrale
- Schlieren-Zurich, Switzerland
- Amministratore Delegato
- Patrick Amstutz
- Dipendenti
- 134
- Quotata dal
- 03.03.2015 (SW:MOLN)
- Azioni in Circolazione
- 38.31 Mln
- Flottante
- 20.71 Mln
- Capitalizzazione di Mercato
- 127.56 Mln CHF
- Insider
- 8.47%
- Investitori Istituzionali
- 43.8%
- Settore (SIC)
- Biological Products, (No Diagnostic Substances)
- Forma Giuridica
- MVII
- ISIN
- US60853G1067
- LEI
- 875500AXMLDAZ4D21744
- P/E
- perdita
- FCF
- −52.0 Mln CHF
- Debito
- ?
- Utili e FCF — per i 12 mesi a 31.12.2025 (l'ultimo rapporto dell'azienda).
Descrizione
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| Old Mission Capital, LLC | 0.03% | 11 347 | 2025-06-30 |
| DFA INVESTMENT DIMENSION… | 0.01% | 3 923 | 2026-07-31 |
| DFA INVESTMENT DIMENSION… | 0.01% | 3 503 | 2026-07-31 |
| American Century ETF Tru… | 0% | 12 | 2026-08-31 |
Accedi con Google